In this episode, Jason Fontana, vice president coronary and renal denervation marketing and strategy at Medtronic, will walk us through Medtronic’s successful entry into the drug-eluting stent market over a decade ago with the Endeavor DES, the first modular drug-eluting stent. With a focus on healing and deliverability, Medtronic overcome a late-start to become a leader of the pack following the approval of the Resolute Integrity DES. We’ll review Medtronic’s current coronary portfolio including Onyx Frontier DES with a dual flex balloon. Fontana will also explain how new technologies and diagnostic techniques will help it set the pace in the coronary space in the future. Thanks to Delve for sponsoring!

Thank you for listening to the MedtronicTalks Podcast.